Bioventus (BVS)
(Delayed Data from NSDQ)
$9.92 USD
+0.04 (0.40%)
Updated Aug 23, 2024 03:59 PM ET
After-Market: $9.93 +0.01 (0.10%) 7:58 PM ET
1-Strong Buy of 5 1
C Value A Growth C Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$9.92 USD
+0.04 (0.40%)
Updated Aug 23, 2024 03:59 PM ET
After-Market: $9.93 +0.01 (0.10%) 7:58 PM ET
1-Strong Buy of 5 1
C Value A Growth C Momentum A VGM
Zacks News
Here's Why You Should Invest in SpringWorks (SWTX) Stock Now
by Zacks Equity Research
Here, we are discussing some reasons why investing in SpringWorks (SWTX) stock now may turn out to be a prudent move.
Galapagos (GLPG) Up on FDA Nod to Begin Phase I/II Lymphoma Study
by Zacks Equity Research
Galapagos (GLPG) rises in pre-market hours on Aug 23, after the FDA nod to begin early to mid-stage study of GLPG5101 for non-Hodgkin lymphoma patients.
Lexicon (LXRX) Up as FDA Maintains Action Date for Zynquista
by Zacks Equity Research
The FDA plans to hold an Advisory Committee meeting to give a recommendation for Lexicon's (LXRX) Zynquista (sotagliflozin) on Oct 31, 2024. Stock up.
Why Grifols (GRFS) Stock Price Moved Up 7% on Wednesday
by Zacks Equity Research
A Bloomberg article suggests that Brookfield Asset Management is in discussions with banks to raise nearly $11 billion to fund the takeover of Spain-based Grifols (GRFS).
Amicus (FOLD) Banks on Galafold, High Dependence a Concern
by Zacks Equity Research
Amicus' (FOLD) lead drug, Galafold, is witnessing solid sales uptake so far. The approval for Pombiliti + Opfolda also aids sales. However, overdependence on Galafold for revenues remains a concern.
J&J (JNJ) to Boost MedTech Business With V-Wave Acquisition
by Zacks Equity Research
Johnson & Johnson (JNJ) inks a definitive agreement to acquire V-Wave Ltd. for an upfront payment of $600 million. The deal is likely to strengthen the company's MedTech business unit further.
GSK's ADC Drug for Lung Cancer Gets FDA's Breakthrough Tag
by Zacks Equity Research
The FDA bestows a Breakthrough Therapy Designation to GSK's B7-H3-targeted antibody-drug conjugate, GSK5764227, for relapsed/refractory extensive-stage small-cell lung cancer.
Zacks Industry Outlook Highlights Corcept, Amneal, Bioventus, Foghorn and Akebia
by Zacks Equity Research
Corcept, Amneal, Bioventus, Foghorn and Akebia have been highlighted in this Industry Outlook article.
5 Small Drug Stocks to Buy as Innovation Reaches Peak
by Kinjel Shah
Innovation is at its peak for the Zacks Medical-Drugs industry. CORT, AMRX, BVS, FHTX, and AKBA may prove to be good additions to one's portfolio.
Merck (MRK) Gets Exclusive Rights to Opevesostat From Partner
by Zacks Equity Research
Merck (MRK) exercises the option that will convert the collaboration deal with partner Orion for prostate cancer candidate opevesostat into a license agreement.
Encompass Health (EHC) Expands in Louisville With New Rehab Unit
by Zacks Equity Research
Encompass Health (EHC) and Baptist Health inaugurate a 40-bed inpatient rehabilitation hospital in Louisville, enhancing regional care and expanding EHC's network to 163 facilities.
Here's Why Investors Must Hold on to Centene (CNC) Stock Now
by Zacks Equity Research
Centene (CNC) is expected to benefit from expanding margins in the Marketplace business, contract wins in Medicaid, and improved Medicare Advantage Star ratings.
Compelling Reasons to Hold on to Cigna (CI) Stock for Now
by Zacks Equity Research
Cigna (CI) remains well-poised for growth on the back of improved pharmacy revenues in its Evernorth unit. Solid cash-generating abilities also enable it to tactically deploy capital.
Here's Why You Should Consider Buying Bioventus (BVS) Stock
by Zacks Equity Research
Here, we discuss some reasons why buying Bioventus (BVS) stock now may turn out to be a prudent move.
J&J (JNJ) Seeks Expanded Use of HIV Drug in US and Europe
by Zacks Equity Research
J&J (JNJ) seeks expanded use of its HIV-1 therapy, Prezcobix, for younger kids in the United States and Europe.
Humana (HUM) Partners With UAB to Boost Care for MA Members
by Zacks Equity Research
Humana (HUM) expands its Medicare Advantage network in Alabama through a new partnership with UAB Health System, offering greater access to enhanced healthcare services.
Biogen (BIIB) Gets EU Approval for Rare Disease Drug Qalsody
by Zacks Equity Research
Biogen's (BIIB) Qalsody is the first therapy approved to treat a rare genetic form of ALS in Europe
Merck (MRK) to Buy Private Ophthalmology Company EyeBio
by Zacks Equity Research
Merck's (MRK) acquisition of EyeBio is set to add the latter's lead pipeline candidate, Restoret, a novel Wnt agonist antibody being developed for treating retinal diseases.
J&J (JNJ) to Buy Rights to Novel Atopic Dermatitis Candidate
by Zacks Equity Research
J&J (JNJ) is set to acquire Yellow Jersey Therapeutics, which holds NM26 rights, from Numab's shareholder, for a purchase price of $1.25 billion in cash.
Here's Why You Should Buy Acrivon Therapeutics (ACRV) Stock
by Zacks Equity Research
Here, we discuss some reasons why buying Acrivon Therapeutics (ACRV) stock now may turn out to be a prudent move.
5 Small Drug Stocks to Buy From a Recovering Industry
by Kinjel Shah
Innovation is expected to continue to drive the growth of the Zacks Medical-Drugs industry. HRTX, BVS, AQST, ACRV and CRDL may prove to be good additions to one's portfolio.
Here's Why You Should Retain Centene (CNC) Stock for Now
by Zacks Equity Research
Centene (CNC) remains well-poised for growth on the back of sound growth in membership, divestitures and a growing cash balance.
PTC Therapeutics (PTCT) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
PTC Therapeutics (PTCT) delivered earnings and revenue surprises of -182.76% and 2.80%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Bioventus (BVS) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
On Bioventus' (BVS) third-quarter 2023 earnings call, investors' focus is likely to be on the sales numbers of its three business units - pain treatments, restorative therapies and surgical solutions.
3 Value Medical Stocks to Buy for Safety Amid Market Volatility
by Indrajit Bandyopadhyay
We have narrowed our search to three value stocks from the Medical sector. These are PHG, RDNT and BVS.